iBio Inc. (IBIO) Skyrockets 49% Upon News of Potential Machine Learning Patent

iBio Inc. (IBIO) skyrocketed 49%, potentially on news of a new patent granted for a “machine learning method for protein modeling to design engineered peptides.” So far, the only source found is from Benzinga and users on StockTwits so the news is unconfirmed.

The most recent press release from IBIO is almost a month ago, when the Company announced the closing of a $3.5 Million public offering.

If true, this patent could be very interesting, with all the new hype surrounding artificial intelligence products, such as Chat GPT.

iBio is a member of the PRISM Vaccines & Cell Therapy Index, which is up 1.4% for the day, largely due to iBio’s performance.

About iBio, Inc.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.

About the Author

iBio Inc. (IBIO) Skyrockets 49% Upon News of Potential Machine Learning Patent

Investors Prism